STAT News – Biotech
STAT+: Insmed drug benefits patients with rare, bacterial lung disease, study shows
Insmed said Monday that the addition of its drug Arikayce to a standard treatment for patients with a rare bacterial lung disease improved respiratory symptoms and increased culture conversion rates.
The study results achieved the goals of a Phase 3 clinical trial designed to show that Arikayce could benefit patients with new occurrences of mycobacterium avium complex (MAC) lung infection who had not yet received antibiotics.
Arikayce was granted accelerated approval in 2018 to treat patients with more advanced MAC lung infection unresponsive to antibiotics.